News Swiss biotech Noema raises $112m for Roche castoffs Cash will fund mid-stage trials in epilepsy, trigeminal neuralgia, and other CNS conditions.
News NICE recommends cannabinoid med for severe epilepsy Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received
News Wales is first UK country to fund GW's Epidyolex for tuberou... Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by
News Swiss start-up Noema raises $59m to develop neurology drugs ... Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
